Armata Pharmaceuticals, Inc. (ARMP)
Automate Your Wheel Strategy on ARMP
With Tiblio's Option Bot, you can configure your own wheel strategy including ARMP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ARMP
- Rev/Share 0.1898
- Book/Share -1.9203
- PB -1.3513
- Debt/Equity -1.59
- CurrentRatio 0.0626
- ROIC -0.8014
- MktCap 94016331.0
- FreeCF/Share -0.8867
- PFCF -2.9296
- PE -3.6536
- Debt/Assets 1.3679
- DivYield 0
- ROE 0.4626
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
All You Need to Know About Armata Pharmaceuticals (ARMP) Rating Upgrade to Buy
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Armata Pharmaceuticals (ARMP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Is Armata Pharmaceuticals (ARMP) Outperforming Other Medical Stocks This Year?
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Armata Pharmaceuticals, Inc. (ARMP) and Avadel (AVDL) have performed compared to their sector so far this year.
Read More
ARMP Soars 72% in a Month Following Infectious Disease Study Success
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Armata Pharmaceuticals stock surges 72% in a month following superior efficacy results from a phase Ib/IIa study of AP-SA02 for treating an infectious disease.
Read More
Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia
Published: May 19, 2025 by: PRNewsWire
Sentiment: Neutral
All primary endpoints for safety, tolerability, and clinical response in the intent-to-treat population met AP-SA02 arm significantly improved clinical outcomes and prevented relapse compared to best available antibiotic therapy No treatment-related serious adverse events were observed with repetitive intravenous dosing LOS ANGELES , May 19, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced positive topline results from its Phase 1b/2a diSArm trial which evaluated AP-SA02, a novel intravenous ("IV") administered multi-phage …
Read More
New Strong Sell Stocks for May 8th
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Negative
ARMP, COLM and EFSI have been added to the Zacks Rank #5 (Strong Sell) List on May 8, 2025.
Read More
Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
Published: May 01, 2025 by: PRNewsWire
Sentiment: Neutral
Phase 1b/2a diSArm trial evaluated AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia Topline data anticipated in Q2 2025 to support potential future pivotal bacteremia efficacy trial LOS ANGELES , May 1, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received an additional $4.65 million of non-dilutive funding pursuant to a previously announced Department of Defense (DoD) award, received through the Medical Technology Enterprise Consortium (MTEC) and …
Read More
New Strong Sell Stocks for April 28th
Published: April 28, 2025 by: Zacks Investment Research
Sentiment: Negative
CCS, ARMP and CABO have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2025.
Read More
About Armata Pharmaceuticals, Inc. (ARMP)
- IPO Date 1994-05-20
- Website https://www.armatapharma.com
- Industry Biotechnology
- CEO Deborah L. Birx
- Employees 60